Stayble initiates clinical phase 2b study in Spain
Stayble Therapeutics today announced that the Company has initiated the first clinic in Spain for its clinical phase 2b study with the drug candidate STA363. Patient recruitment will commence immediately. The Company has now initiated clinics in all the three countries where it plans to conduct the study: the Netherlands, Russia and Spain. STA363 is intended for patients suffering from chronic disc-related low back pain.CEO Andreas Gerward comments: COVID-19, and hence the access to healthcare services, has posed a challenge to us in our effort to initiate clinics. The fact that we now have